SEC Form SC 13G/A filed by Aerie Pharmaceuticals Inc. (Amendment)

$AERI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $AERI alert in real time by email
SC 13G/A 1 e621283_sc13ga-aerie.htm

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

SCHEDULE 13G

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

 

(Amendment No. 1) *

 

Aerie Pharmaceuticals, Inc.

(Name of Issuer)

 

Common Stock

(Title of Class of Securities)

 

00771V108

(CUSIP Number)

 

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

Rule 13d-1(b)

 

Rule 13d-1(c)

 

Rule 13d-1(d)

 

(Page 1 of 11 Pages)

 

----------

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

CUSIP No. 00771V108 13G Page 2 of 11

 

1.

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 

Deerfield Mgmt, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

 

(a) ☐

(b) ☒

3.

SEC USE ONLY

 

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

 

 

 NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

SOLE VOTING POWER

 

0

 
6.

SHARED VOTING POWER

 

4,200,804 (1)

 

7.

 

SOLE DISPOSITIVE POWER

 

0

 

8.

 

SHARED DISPOSITIVE POWER

 

4,200,804 (1)

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,200,804 (1)

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

8.87%

12.

TYPE OF REPORTING PERSON*

 

PN

__________________

(1) Comprised of shares of common stock held by Deerfield Partners, L.P., of which Deerfield Mgmt, L.P. is the general partner.

 

CUSIP No. 00771V108 13G Page 3 of 11

 

1.

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 

Deerfield Management Company, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

 

(a) ☐

(b) ☒

3.

SEC USE ONLY

 

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

 

 

 NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

SOLE VOTING POWER

 

0

 
6.

SHARED VOTING POWER

 

4,695,020 (2)

 

7.

 

SOLE DISPOSITIVE POWER

 

0

 

8.

 

SHARED DISPOSITIVE POWER

 

4,695,020 (2)

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,695,020 (2)

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

9.91%

12.

TYPE OF REPORTING PERSON*

 

PN

__________________

(2) Comprised of shares of common stock held by Deerfield Partners, L.P. and Deerfield Private Design Fund III, L.P., of which Deerfield Management Company, L.P. is the investment advisor.

 

CUSIP No. 00771V108 13G Page 4 of 11

 

1.

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 

Deerfield Partners, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

 

(a) ☐

(b) ☒

3.

SEC USE ONLY

 

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

 

 

 NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

SOLE VOTING POWER

 

0

 
6.

SHARED VOTING POWER

 

4,200,804

 

7.

 

SOLE DISPOSITIVE POWER

 

0

 

8.

 

SHARED DISPOSITIVE POWER

 

4,200,804

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,200,804

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

8.87%

12.

TYPE OF REPORTING PERSON*

 

PN 

 

CUSIP No. 00771V108 13G Page 5 of 11

 

1.

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 

Deerfield Mgmt III, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

 

(a) ☐

(b) ☒

3.

SEC USE ONLY

 

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

 

 

 NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

SOLE VOTING POWER

 

0

 
6.

SHARED VOTING POWER

 

494,216 (3)

 

7.

 

SOLE DISPOSITIVE POWER

 

0

 

8.

 

SHARED DISPOSITIVE POWER

 

494,216 (3)

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

494,216 (3)

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

1.04%

12.

TYPE OF REPORTING PERSON*

 

PN

_________________

(3) Comprised of shares of common stock held by Deerfield Private Design Fund III, L.P., of which Deerfield Mgmt III, L.P. is the general partner.

 

CUSIP No. 00771V108 13G Page 6 of 11

 

1.

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 

Deerfield Private Design Fund III, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

 

(a) ☐

(b) ☒

3.

SEC USE ONLY

 

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

 

 

 NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

SOLE VOTING POWER

 

0

 
6.

SHARED VOTING POWER

 

494,216

 

7.

 

SOLE DISPOSITIVE POWER

 

0

 

8.

 

SHARED DISPOSITIVE POWER

 

494,216

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

494,216

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

1.04%

12.

TYPE OF REPORTING PERSON*

 

PN

 

CUSIP No. 00771V108 13G Page 7 of 11

 

1.

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 

James E. Flynn

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

 

(a) ☐

(b) ☒

3.

SEC USE ONLY

 

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States

 

 

 NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

SOLE VOTING POWER

 

0

 
6.

SHARED VOTING POWER

 

4,695,020 (4)

 

7.

 

SOLE DISPOSITIVE POWER

 

0

 

8.

 

SHARED DISPOSITIVE POWER

 

4,695,020 (4)

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,695,020 (4)

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

9.91%

12.

TYPE OF REPORTING PERSON*

 

IN

__________________ 

(4) Comprised of shares of common stock held by Deerfield Partners, L.P. and Deerfield Private Design Fund III, L.P. 

 

CUSIP No. 00771V108 13G Page 8 of 11

 

Item 1(a). Name of Issuer:
   
 

Aerie Pharmaceuticals, Inc.

   
Item 1(b). Address of Issuer's Principal Executive Offices:
   
 

4301 Emperor Boulevard, Suite 400

Durham, North Carolina 27703

   
Item 2(a). Name of Person Filing:
   
 

James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P. and Deerfield Private Design Fund III, L.P.

   
Item 2(b). Address of Principal Business Office, or if None, Residence:
   
 

James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Partners, L.P., Deerfield Management Company, L.P., and Deerfield Private Design Fund III, L.P., 345 Park Avenue South, 12 Floor, New York, NY 10010

   
Item 2(c). Citizenship:
   
 

Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., Deerfield Mgmt III, L.P., and Deerfield Private Design Fund III, L.P. - Delaware limited partnerships

 

James E. Flynn – United States citizen

   
Item 2(d). Title of Class of Securities:
   
 

Common Stock

   
Item 2(e). CUSIP Number:
   
 

00771V108

     
Item 3.

If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

   
(a)

Broker or dealer registered under Section 15 of the Exchange Act.

     
(b) Bank as defined in Section 3(a)(6) of the Exchange Act.
     
(c)

Insurance company as defined in Section 3(a)(19) of the Exchange Act.

     
(d)

Investment company registered under Section 8 of the Investment Company Act.

     
(e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
     
(f)

An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     
(g)

A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

(h)

A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     
(i)

A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

 

CUSIP No. 00771V108 13G Page 9 of 11

 

     
(j) A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
     
(k) Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

 

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________

 

Item 4. Ownership.
       

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

       
(a) Amount beneficially owned**:  
       
 

Deerfield Mgmt, L.P. - 4,200,804 shares

Deerfield Management Company, L.P. – 4,695,020 shares

Deerfield Mgmt III, L.P. – 494,216 shares

Deerfield Partners, L.P. - 4,200,804 shares

Deerfield Private Design Fund III, L.P. - 494,216 shares

James E. Flynn – 4,695,020 shares

       
(b) Percent of class**:  
       
 

Deerfield Mgmt, L.P. – 8.87%

Deerfield Management Company, L.P. – 9.91%

Deerfield Mgmt III, L.P. – 1.04%

Deerfield Partners, L.P. – 8.87%

Deerfield Private Design Fund III, L.P. – 1.04%

James E. Flynn – 9.91%

       
(c) Number of shares as to which such person has**:  
       
  (i) Sole power to vote or to direct the vote: All Reporting Persons - 0
       
  (ii) Shared power to vote or to direct the vote:

Deerfield Mgmt, L.P. - 4,200,804

Deerfield Management Company, L.P. – 4,695,020

Deerfield Mgmt III, L.P. - 494,216

Deerfield Partners, L.P. - 4,200,804

Deerfield Private Design Fund III, L.P. - 494,216

James E. Flynn – 4,695,020

       
  (iii)

Sole power to dispose or to direct the disposition of:

All Reporting Persons - 0
       
  (iv)

Shared power to dispose or to direct the disposition of:

Deerfield Mgmt, L.P. - 4,200,804

Deerfield Management Company, L.P. – 4,695,020

Deerfield Mgmt III, L.P. - 494,216

Deerfield Partners, L.P. - 4,200,804

Deerfield Private Design Fund III, L.P. - 494,216

James E. Flynn – 4,695,020

  

**See footnotes on cover pages which are incorporated by reference herein.

 

CUSIP No. 00771V108 13G Page 10 of 11

 

Item 5. Ownership of Five Percent or Less of a Class.
   

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following ☐.

   
   
   
Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
   

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

   
  N/A
   
Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

   

If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

   
  N/A
   
Item 8. Identification and Classification of Members of the Group.
   

If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

   
  See Exhibit B
   
Item 9. Notice of Dissolution of Group.
   

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

   
  N/A
   
Item 10. Certifications.
   

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11."

 

CUSIP No. 00771V108 13G Page 11 of 11

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

DEERFIELD MGMT, L.P.

By: J.E. Flynn Capital, LLC, General Partner

 

By: /s/ Jonathan Isler 

       Jonathan Isler, Attorney-In-Fact

 

DEERFIELD MANAGEMENT COMPANY, L.P.

By: Flynn Management LLC, General Partner

 

By: /s/ Jonathan Isler 

       Jonathan Isler, Attorney-In-Fact

 

DEERFIELD MGMT III, L.P.

By: J.E. Flynn Capital III, LLC, General Partner

 

By: /s/ Jonathan Isler 

       Jonathan Isler, Attorney-In-Fact

 

DEERFIELD PARTNERS, L.P.

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

 

By: /s/ Jonathan Isler 

       Jonathan Isler, Attorney-In-Fact

 

DEERFIELD PRIVATE DESIGN FUND III, L.P.

By: Deerfield Mgmt III, L.P., General Partner

By: J.E. Flynn Capital III, LLC, General Partner

 

By: /s/ Jonathan Isler 

       Jonathan Isler, Attorney-In-Fact

 

JAMES E. FLYNN

 

/s/ Jonathan Isler 

Jonathan Isler, Attorney-In-Fact

 

Date: February 11, 2022

 

 

Exhibit List

 

Exhibit A. Joint Filing Agreement.

 

Exhibit B. Item 8 Statement.

 

Exhibit C. Power of Attorney (1).

 

(1) Power of Attorney previously filed as Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn.

 

 

Exhibit A

 

Joint Filing Agreement

 

The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Aerie Pharmaceuticals, Inc. shall be filed on behalf of the undersigned.

 

DEERFIELD MGMT, L.P.

By: J.E. Flynn Capital, LLC, General Partner

 

By: /s/ Jonathan Isler 

       Jonathan Isler, Attorney-In-Fact

 

DEERFIELD MANAGEMENT COMPANY, L.P.

By: Flynn Management LLC, General Partner

 

By: /s/ Jonathan Isler 

       Jonathan Isler, Attorney-In-Fact

 

DEERFIELD MGMT III, L.P.

By: J.E. Flynn Capital III, LLC, General Partner

 

By: /s/ Jonathan Isler 

       Jonathan Isler, Attorney-In-Fact

 

DEERFIELD PARTNERS, L.P. 

By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner

 

By: /s/ Jonathan Isler 

       Jonathan Isler, Attorney-In-Fact

 

DEERFIELD PRIVATE DESIGN FUND III, L.P.

By: Deerfield Mgmt III, L.P., General Partner

By: J.E. Flynn Capital III, LLC, General Partner

 

By: /s/ Jonathan Isler 

       Jonathan Isler, Attorney-In-Fact

 

JAMES E. FLYNN

 

/s/ Jonathan Isler 

Jonathan Isler, Attorney-In-Fact

 

 

Exhibit B

 

Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.

 

Get the next $AERI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AERI

DatePrice TargetRatingAnalyst
8/29/2022$14.00 → $15.25Buy → Neutral
Citigroup
8/23/2022Buy → Hold
Needham
8/23/2022$30.00 → $15.25Overweight → Neutral
Cantor Fitzgerald
2/25/2022$22.00 → $14.00Buy
Needham
11/5/2021$24.00 → $22.00Buy
Needham
8/5/2021$26.00 → $24.00Buy
Needham
More analyst ratings

$AERI
Press Releases

Fastest customizable press release news feed in the world

See more
  • Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical Business

    Leveraging Alcon's robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon's presence in the $20 billion global ophthalmic pharmaceutical category1 Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))). This transaction helps bolster Alcon's presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pi

    $AERI
    $ALC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Ophthalmic Goods
  • Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results

    Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022. "Aerie delivered another solid performance in the third quarter and executed well across our three strategic pillars of growth. Our first-in-class glaucoma franchise showed strong continued year-over-year growth, in line with our expect

    $AERI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options

    Webinar to be held Friday, September 23, 2022 @ 10 a.m. ET Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that it will host a Key Opinion Leader (KOL) webinar on Friday, September 23, 2022 from 10:00 a.m. – 11:30 a.m. Eastern Time. The event will feature Dr. Laura Periman, MD, of the Periman Eye Institute, and Dr. John Sheppard, MD, of the Virginia Eye Consultants, who will discuss New Perspectives on Dry Eye Disease (DED), including the Current Landscape, Unmet Medical Needs, and Emerging Treatment Options, including Aerie's investigational TRPM8 agoni

    $AERI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$AERI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AERI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AERI
SEC Filings

See more

$AERI
Leadership Updates

Live Leadership Updates

See more
  • Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer

    Finance executive with a successful track record in capital creation, deployment, and optimization Brings breadth of finance, strategy and business development experience Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Peter F. Lang will join the Company as Chief Financial Officer, effective March 18, 2022. He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals and become a member of the Aerie Executive Committee. "I am pleased to welcome Peter to our leadership team," said Raj Kannan, Chief Executive Officer. "His extensive e

    $AERI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Aerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical Officer

    Fellowship-trained Ophthalmologist and well-rounded biopharmaceutical executive brings breadth of clinical development, medical affairs, strategy, and business development experience Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Gary Sternberg, M.D., M.B.A., will join the Company as Chief Medical Officer (CMO), effective March 1, 2022. He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals and become a member of the Aerie Executive Committee. Gary is an Ophthalmologist who is fellowship trained in cornea and external disease

    $AERI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer

    An accomplished leader Brings a depth and breadth of commercial, business development, and portfolio strategy experience Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that Raj Kannan will join the Company as Chief Executive Officer and a director, effective December 20, 2021. "On behalf of the Board of Directors, I am very pleased to welcome Raj Kannan to Aerie. During the search process, the Board was pleased to interview several strong candidates and Raj rose to the top of the list during the process. Raj brings a track record of building effective organizations and teams, launching and growing products in the U.S. and globally, buildi

    $AERI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$AERI
Financials

Live finance-specific insights

See more
  • Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical Business

    Leveraging Alcon's robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon's presence in the $20 billion global ophthalmic pharmaceutical category1 Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))). This transaction helps bolster Alcon's presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pi

    $AERI
    $ALC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Ophthalmic Goods
  • Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results

    Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022. "Aerie delivered another solid performance in the third quarter and executed well across our three strategic pillars of growth. Our first-in-class glaucoma franchise showed strong continued year-over-year growth, in line with our expect

    $AERI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio

    Builds on Alcon's existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment1 Adds Rocklatan® and Rhopressa®, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates Transaction values Aerie at approximately $770 million in equity value and is expected to be accretive to Alcon's core diluted EPS in 2024 Ad hoc announcement pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))), a pharmaceutical company focused on the discovery, development, manufacturing and commercialization of first-in

    $AERI
    $ALC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Ophthalmic Goods

$AERI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more